Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 250

Sort by

Sort Order Select

Journal Articles

First Disclosure of AZD9829, a TOP1i-ADC Targeting CD123: Promising Preclinical Activity in AML Models with Minimal Effect on Healthy Progenitors

Blood (2023) 142 (Supplement 1): 5957.

https://doi.org/10.1182/blood-2023-187642

Published: 2023

Journal Articles

Multi-Cancer Early Detection Test Is Sensitive and Accurate in Detecting Shared DNA Methylation Signal in a Variety of Lymphoid and Plasma Cell Neoplasms

Candace Westgate, Gilles Salles, Stephannie Shih, Margarita Lopatin, Kathryn N. Kurtzman, Katerina Kappes, Oliver Venn, Samir Parekh, Jeffrey M. Venstrom, Anas Younes, Rita Shaknovich

Blood (2023) 142 (Supplement 1): 3646.

https://doi.org/10.1182/blood-2023-186481

Published: 2023

Journal Articles

Epigenetic Silencing of MTAP in Hodgkin's Lymphoma Renders It Sensitive to a 2 nd Generation PRMT5 Inhibitor

Jelena Urosevic, James T. Lynch, Stefanie Meyer, Nevin Yusufova, Elizabeth Wiseman, Paul Waring, Ted Hong, Zuleyha Ozen, Haiyun Wang, Lauren Bradshaw, Hannah Tomczak, Ho Man Chan, Ruben Reyes, Susan Critchlow, Anas Younes, Emma Dean

Blood (2023) 142 (Supplement 1): 4185.

https://doi.org/10.1182/blood-2023-174445

Published: 2023

Journal Articles

Potentiating antibody-dependent killing of cancers with CAR T cells secreting CD47-SIRPα checkpoint blocker

Megan M. Dacek, Keifer G. Kurtz, Patrick Wallisch, Stephanie A. Pierre, Shireen Khayat, Christopher M. Bourne, Thomas J. Gardner, Kristen C. Vogt, Nica Aquino, Anas Younes, David A. Scheinberg

Blood (2023) 141 (16): 2003–2015.

https://doi.org/10.1182/blood.2022016101

Published: 2023

Includes: Supplemental data

Journal Articles

Brentuximab Vedotin Combined with Chemotherapy in Newly Diagnosed, Early-Stage, Unfavorable-Risk Hodgkin Lymphoma: Extended Follow-up with Evaluation of Baseline Metabolic Tumor Volume and PET2

Blood (2022) 140 (Supplement 1): 1756–1758.

https://doi.org/10.1182/blood-2022-156382

Published: 2022

Journal Articles

Molecular Profiling across Lymphoma Subtypes Using MSK-Impact Next Generation Sequencing

Blood (2022) 140 (Supplement 1): 9251–9253.

https://doi.org/10.1182/blood-2022-158783

Published: 2022

Journal Articles

Interim Efficacy Analysis of a Phase II Study Demonstrates Promising Activity of the Combination of Pembrolizumab (PEM) and Entinostat (ENT) in Relapsed and Refractory (R/R) Hodgkin Lymphoma (HL)

Blood (2021) 138 (Supplement 1): 2447.

https://doi.org/10.1182/blood-2021-154226

Published: 2021

Journal Articles

TP53 Mutations and RNA Binding Protein Musashi 2 Drive Resistance to PRMT5-Targeted Therapy in B-Cell Lymphoma

Ingrid Tatiana Erazo, Chiara M Evans, Daniel Zakheim, Karen L Chu, Olena Barbash, Alice Yunsi Refermat, Connie Lee Batlevi, Anas Younes, Michael G Kharas

Blood (2021) 138 (Supplement 1): 788.

https://doi.org/10.1182/blood-2021-151280

Published: 2021

Journal Articles

PK and PD Assessment of BET Inhibitor Pelabresib (CPI-0610) in Patients with Relapsed or Refractory Lymphoma: Findings from a Phase 1 Study

Kristie A. Blum, Jeffrey G. Supko, Michael Maris, Ian W. Flinn, Andre H. Goy, Anas Younes, Suresh Bobba, Adrian Senderowicz, Sergey Efuni, Ronda Rippley, Jeremy S. Abramson

Blood (2021) 138 (Supplement 1): 1202.

https://doi.org/10.1182/blood-2021-150852

Published: 2021

Journal Articles

Tumor-targeted nanoparticles improve the therapeutic index of BCL2 and MCL1 dual inhibition

Neeta Bala Tannan, Mandana T. Manzari, Laurie Herviou, Mariana Da Silva Ferreira, Connor Hagen, Hiroto Kiguchi, Katia Manova-Todorova, Venkatraman Seshan, Elisa de Stanchina, Daniel A. Heller, Anas Younes

Blood (2021) 137 (15): 2057–2069.

https://doi.org/10.1182/blood.2020008017

Published: 2021

Includes: Supplemental data

Journal Articles

Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era

Blood (2021) 137 (1): 39–48.

https://doi.org/10.1182/blood.2020005112

Published: 2021

Includes: Supplemental data

Journal Articles

Brentuximab Vedotin with Chemotherapy for Patients with Previously Untreated, Stage III/IV Classical Hodgkin Lymphoma: 5-Year Update of the ECHELON-1 Study

Blood (2020) 136 (Supplement 1): 26–28.

https://doi.org/10.1182/blood-2020-137089

Published: 2020

Journal Articles

R-CHOP Versus R-Bendamustine with or without Rituximab Maintenance in Newly Diagnosed Follicular Lymphoma Patients with High SUV at Baseline PET

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-136438

Published: 2020

Journal Articles

Interim Analysis from a Prospective Multicenter Study of Next-Generation Sequencing Minimal Residual Disease Assessment and CT Monitoring for Surveillance after Frontline Treatment in Diffuse Large B-Cell Lymphoma

Blood (2020) 136 (Supplement 1): 46–47.

https://doi.org/10.1182/blood-2020-138889

Published: 2020

Journal Articles

Frontline Sequential Immunochemotherapy Plus Lenalidomide for Mantle Cell Lymphoma Incorporating MRD Evaluation: Phase II, Investigator-Initiated, Single-Center Study

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-136565

Published: 2020

Journal Articles

Recil 2017 Criteria Demonstrated Similar Prognostic Value and Detected a Comparable Treatment Difference between Obinutuzumab- and Rituximab-Chemotherapy Compared with Cheson 2007 and Lugano 2014 Criteria in Patients with Previously Untreated Advanced-Stage Follicular Lymphoma

Lale Kostakoglu, MD MPH, Andrew Davies, MD PhD, Michael Herold, Wolfgang Hiddemann, Robert Marcus, Judith Trotman, FRACP, Andrea Knapp, Federico Mattiello, Tina G Nielsen, Deniz Sahin, Carol Ward, Anas Younes

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-134784

Published: 2020

Journal Articles

Safety, Pharmacokinetics and Activity of CA-4948, an IRAK4 Inhibitor, for Treatment of Patients with Relapsed or Refractory Hematologic Malignancies: Results from the Phase 1 Study

Grzegorz S. Nowakowski, MD, Lori A. Leslie, MD, Anas Younes, Allison C. Rosenthal, D.O., Matthew A. Lunning, DO, FACP, Krish Patel, MD, Daniel J. Landsburg, MD, Elizabeth Martinez, PhD DHSC, MSN, Reinhard von Roemeling, MD, Christopher Lieberman, Han W. Tun, MD

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-140857

Published: 2020

Journal Articles

Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study

Blood (2020) 135 (10): 735–742.

https://doi.org/10.1182/blood.2019003127

Published: 2020

Includes: Supplemental data

Journal Articles

Central Nervous System Prophylaxis with High-Dose Intravenous Methotrexate or Intrathecal Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma and High-Risk of CNS Relapse Treated in the Rituximab Era

Blood (2019) 134 (Supplement_1): 1619.

https://doi.org/10.1182/blood-2019-131435

Published: 2019

Journal Articles

Genomic Profiling of Mantle Cell Lymphoma Suggests Poor-Risk Profile Is Present at Diagnosis and Does Not Arise By Tumor Evolution

Erel Joffe, MDMSc, Anita Kumar, MD, Serena Zheng, Manik Uppal, Kurt S. Bantilan, MPH, Preston Atteberry, David J. Straus, MD, M. Lia Palomba, MD, Ariela Noy, MD, Steven M. Horwitz, MD, Alison J. Moskowitz, MD, Paul A. Hamlin, MD, Matthew J Matasar, MD, Connie Lee Batlevi, MD PhD, Gottfried R. von Keudell, MD PhD, Ahmet Dogan, MDPhD, Anas Younes, MD, Andrew D. Zelenetz, MD PhD

Blood (2019) 134 (Supplement_1): 22.

https://doi.org/10.1182/blood-2019-129563

Published: 2019

NARROW

First Disclosure of AZD9829, a TOP1i-ADC Targeting CD123: Promising Preclinical Activity in AML Models with Minimal Effect on Healthy Progenitors

Multi-Cancer Early Detection Test Is Sensitive and Accurate in Detecting Shared DNA Methylation Signal in a Variety of Lymphoid and Plasma Cell Neoplasms

Epigenetic Silencing of MTAP in Hodgkin's Lymphoma Renders It Sensitive to a 2 nd Generation PRMT5 Inhibitor

Potentiating antibody-dependent killing of cancers with CAR T cells secreting CD47-SIRPα checkpoint blocker

Brentuximab Vedotin Combined with Chemotherapy in Newly Diagnosed, Early-Stage, Unfavorable-Risk Hodgkin Lymphoma: Extended Follow-up with Evaluation of Baseline Metabolic Tumor Volume and PET2

Molecular Profiling across Lymphoma Subtypes Using MSK-Impact Next Generation Sequencing

Interim Efficacy Analysis of a Phase II Study Demonstrates Promising Activity of the Combination of Pembrolizumab (PEM) and Entinostat (ENT) in Relapsed and Refractory (R/R) Hodgkin Lymphoma (HL)

TP53 Mutations and RNA Binding Protein Musashi 2 Drive Resistance to PRMT5-Targeted Therapy in B-Cell Lymphoma

PK and PD Assessment of BET Inhibitor Pelabresib (CPI-0610) in Patients with Relapsed or Refractory Lymphoma: Findings from a Phase 1 Study

Tumor-targeted nanoparticles improve the therapeutic index of BCL2 and MCL1 dual inhibition

Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era

Brentuximab Vedotin with Chemotherapy for Patients with Previously Untreated, Stage III/IV Classical Hodgkin Lymphoma: 5-Year Update of the ECHELON-1 Study

R-CHOP Versus R-Bendamustine with or without Rituximab Maintenance in Newly Diagnosed Follicular Lymphoma Patients with High SUV at Baseline PET

Interim Analysis from a Prospective Multicenter Study of Next-Generation Sequencing Minimal Residual Disease Assessment and CT Monitoring for Surveillance after Frontline Treatment in Diffuse Large B-Cell Lymphoma

Frontline Sequential Immunochemotherapy Plus Lenalidomide for Mantle Cell Lymphoma Incorporating MRD Evaluation: Phase II, Investigator-Initiated, Single-Center Study

Recil 2017 Criteria Demonstrated Similar Prognostic Value and Detected a Comparable Treatment Difference between Obinutuzumab- and Rituximab-Chemotherapy Compared with Cheson 2007 and Lugano 2014 Criteria in Patients with Previously Untreated Advanced-Stage Follicular Lymphoma

Safety, Pharmacokinetics and Activity of CA-4948, an IRAK4 Inhibitor, for Treatment of Patients with Relapsed or Refractory Hematologic Malignancies: Results from the Phase 1 Study

Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study

Central Nervous System Prophylaxis with High-Dose Intravenous Methotrexate or Intrathecal Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma and High-Risk of CNS Relapse Treated in the Rituximab Era

Genomic Profiling of Mantle Cell Lymphoma Suggests Poor-Risk Profile Is Present at Diagnosis and Does Not Arise By Tumor Evolution

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only